man
without
medic
histori
present
dizzi
syncop
report
fever
product
cough
dyspnea
myalgia
four
day
exam
afebril
normotens
tachycard
beatsmin
tachypn
breathsmin
oxygen
satur
room
air
bmi
physic
exam
unremark
except
bibasilar
crackl
laboratori
valu
follow
carbon
dioxid
mmoll
creatinin
mgdl
whitebloodcel
count
neutrophil
hemoglobin
gdl
platelet
count
hiv
neg
arteri
blood
ga
room
air
ph
mmhg
mmhg
oxygen
satur
chest
xray
show
bibasilar
atelectasi
left
pleural
effus
patient
admit
pneumonia
treat
ceftriaxon
azithromycin
oseltamivir
diagnos
serum
pcr
becam
increasingli
tachypn
ratio
fell
intub
chest
xray
show
worsen
bilater
infiltr
antibiot
chang
linezolid
piperacillintazobactam
moxifloxacin
develop
septic
shock
acut
respiratori
distress
syndrom
ard
acut
kidney
injuri
requir
hemodialysi
receiv
vasopressor
corticosteroid
lowtid
volum
prone
ventil
bronchoalveolar
lavag
bal
fluid
grew
resist
p
aeruginosa
antibiot
chang
imipenemcilastatin
tobramycin
ciprofloxacin
hospit
day
chest
ct
show
diffus
interstiti
alveolar
infiltr
pulmonari
embolu
hospit
day
patient
develop
massiv
hemoptysi
cardiac
arrest
expir
autopsi
reveal
alveoli
collaps
extens
organ
diffus
alveolar
damag
hemorrhag
suspect
caus
death
bacteri
coinfect
ard
alveolar
hemorrhag
cdc
report
found
coinfect
fatal
case
ventilatorassociatedpseudomona
like
exacerb
sever
viral
pneumonia
addit
report
histopatholog
studi
show
diffus
alveolar
damag
necrot
bronchiol
alveolar
hemorrhag
secondari
infect
focal
alveolar
necrosi
alveolar
hemorrhag
known
complic
influenza
describ
infect
patient
section
right
middl
lobe
reveal
necrosi
aspergillu
invad
larg
blood
vessel
blood
bal
cultur
show
fungal
growth
diagnosi
ia
made
histolog
respiratori
cultur
sensit
aspergillosi
galactomannan
bal
sensit
specif
invas
aspergillosi
seem
predomin
caus
death
patient
report
pandem
well
viral
pneumonia
includ
sever
acut
respiratori
syndrom
outbreak
ia
typic
occur
immunocompromis
patient
caus
pulmonari
hemorrhag
mechan
propens
aspergillu
angioinvas
document
glucocorticoidtr
nonneutropen
patient
extens
necrosi
less
angioinvas
lower
fungal
burden
suggest
inflammationdriven
patholog
influenza
may
induc
glucocorticoid
compromis
innat
host
defens
may
caus
immunodysregul
refractori
shock
patient
receiv
hydrocortison
mg
iv
divid
dose
taper
arrest
day
later
nonneutropen
patient
receiv
caspofungin
empir
expir
three
day
later
caspofungin
approv
treatment
ia
patient
toler
refractori
standard
therapi
one
trial
caspofungin
overal
complet
partial
respons
rate
trial
case
report
note
breakthrough
rate
report
fatal
case
invas
aspergillosi
previous
healthi
man
infect
influenza
given
rapid
symptomonset
deterior
clinician
must
vigil
promptli
diagnos
treat
influenzalik
ill
antibiot
bacteri
coinfect
antifung
therapi
consid
final
corticosteroid
patient
influenza
may
pose
risk
invas
fungal
infect
